RaySearch Laboratories AB stock analysis
RaySearch Laboratories AB (0GRZ) Share Price & Analysis
0GRZ Stock Chart & Stats
- Day’s Range
- SEK 171.10 - SEK 173.90
- 52-Week Range
- SEK 161.00 - SEK 237.00
- Previous Close
- SEK 172.25
- Volume
- N/A
- Average Volume (3M)
- 24.82K
- Market Cap
- SEK 5.87B
- Enterprise Value
- SEK 6.49B
- Total Cash (Recent Filing)
- SEK 158.30M
- Total Debt (Recent Filing)
- SEK 406.00M
- Price to Earnings (P/E)
- 28.4
- Beta
- 0.89
- Next Earnings
- Feb 10, 2027 (Est.)
- EPS Estimate
- 2.81
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.84%
Bulls Say, Bears Say
Bulls Say
Recurring Revenue And Sales Growth
Record quarterly sales and a meaningful recurring support base indicate broad customer adoption and continuing revenue visibility. Support income can make the business more resilient than one-off license sales, while ongoing growth supports investment in product development and market expansion.
Strong Demand And Backlog
Accelerating order intake and a substantial backlog provide evidence of demand that can support revenue over the next several quarters. Conversion opportunities in the coming 12 months, together with strong proton and photon interest, reinforce RaySearch’s market position.
Financial Flexibility
Net cash and available credit provide meaningful flexibility to fund product development, customer deployments and strategic growth without relying heavily on additional borrowing. This financial position also improves resilience while the company manages uneven order timing and investment needs.
Bears Say
Margin Pressure From Hardware Mix
The sharp margin decline shows that revenue growth does not automatically translate into comparable earnings growth. Hardware-heavy sales and related cost pressure can dilute the economics of the software model, while management’s full-year margin target remains dependent on an exceptionally strong quarter.
Receivables And Cash-flow Volatility
Negative quarterly free cash flow and elevated receivables indicate that reported sales are not always converting promptly into cash. Persistent longer payment terms could tie up working capital, reduce funding flexibility and make cash generation more volatile even when underlying demand remains healthy.
Gradual RayCare Monetization
RayCare offers an important avenue for expanding beyond treatment planning, but slow conversion from customer interest to signed deals delays its contribution to growth. Continued implementation and purchasing delays could limit near-term platform monetization and increase reliance on the established RayStation business.
RaySearch Laboratories AB News
0GRZ FAQ
What was RaySearch Laboratories AB’s price range in the past 12 months?
What is RaySearch Laboratories AB’s market cap?
When is RaySearch Laboratories AB’s upcoming earnings report date?
How were RaySearch Laboratories AB’s earnings last quarter?
Is RaySearch Laboratories AB overvalued?
Does RaySearch Laboratories AB pay dividends?
What is RaySearch Laboratories AB’s EPS estimate?
How many shares outstanding does RaySearch Laboratories AB have?
What happened to RaySearch Laboratories AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of RaySearch Laboratories AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
RaySearch Laboratories AB
RaySearch Laboratories AB (publ) is a global medical technology company dedicated to developing cutting-edge software solutions for cancer treatment. Its principal offering, RayStation, is a sophisticated treatment planning system that supports a vast range of clinical activities. These capabilities include automated planning, adaptive therapy, multi-criteria optimization, rapid and accurate dose calculations, OAR dose reduction, robustness modeling, machine learning integration, and support for advanced radiation modalities such as VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomotherapy, stereotactic treatments, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also offers RayPlan, another treatment planning system specifically designed for various radiation therapy methods including 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy. For managing oncology workflows, RayCare serves as a dedicated information system. Additionally, RaySearch provides RayCommand, a flexible treatment control system compatible with diverse hardware and designed to manage advanced functionalities of treatment machines and software. To leverage patient data, its cloud-based oncology analytics system, RayIntelligence, converts raw information into valuable insights. RaySearch Laboratories AB (publ) further provides training courses for its products and is headquartered in Stockholm, Sweden.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Johan Lof
- Employees
- 464
- Website
- www.raysearchlabs.com
- Address
- Eugeniavägen 18C, Stockholm, AB, 113 68, SE
RaySearch Laboratories AB (0GRZ) Earnings & Revenues
0GRZ Company Deck
0GRZ Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, supported by record Q3 sales, strong order intake, U.S. momentum, strategic customer wins, expanding RayCare adoption, substantial backlog and strong financial flexibility. However, license sales declined, margins were pressured by an unusually high hardware mix, free cash flow was negative, RayCare deal conversion remains gradual, reimbursement-related delays persist, and the full-year EBIT target requires an exceptionally strong fourth quarter.
View all GB:0GRZ earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |










